About
Small Molecules, Biologics
Areas of Focus
Categories
Biologics & BiopharmaceuticalSmall Molecule Pharmaceutical
Team (5)
Clinical Trials (14)
View allTotal Trials
14
As Lead Sponsor
11
As Collaborator
3
Total Enrollment
2,303
By Phase
PHASE2: 6PHASE1: 6PHASE3: 1PHASE2/PHASE3: 1
By Status
COMPLETED: 12ACTIVE_NOT_RECRUITING: 1TERMINATED: 1
Clinical Trials Pipeline14 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
Today
Hover over trial bars to see details
Recent Trials
NCT06327100Collaborator
Open Label Phase 2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
PHASE2Active, not recruiting
1 participants
Started: Aug 1, 2024 · Completed: May 1, 2031
NCT05187403Lead Sponsor
A Study of Laquinimod Eye-drops in Healthy Participants
PHASE1Completed
54 participants
Started: Dec 9, 2021 · Completed: Jan 19, 2023
NCT04405167Collaborator
Tasquinimod for the Treatment of Relapsed or Refractory Myeloma
PHASE1Terminated
30 participants
Started: Jul 10, 2020 · Completed: Jul 1, 2025
NCT02159950Collaborator
Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
PHASE2Completed
2 participants
Started: Jan 31, 2015
NCT01487551Lead Sponsor
An Open-Label Study to Evaluate Biomarkers and Safety in Systemic Sclerosis Patients Treated With ABR-215757 (Paquinimod)
PHASE2Completed
9 participants
Started: Dec 31, 2011 · Completed: Feb 28, 2013
Locations (1)
Headquarters
Lund, Sweden
Map
Loading map...